In healthy postmenopausal women, what are the effects of calcium citrate compared with a placebo on serum calcium, blood pressure and blood coagulation?

niversity of Auckland0 个研究点目标入组 40 人开始时间: 2014年8月13日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Female, postmenopausal 5 years or more (menopause defined as at least 12 months since last period in a woman aged > 45 yrs with intact uterus, or serum oestradiol < 100 pmol/l with FSH > 50 IU/l in younger or hysterectomised women).

•Current smoker, current use of Warfarin, aspirin or other blood thinning medications, diabetes, current use of blood pressure medication, past history of coronary heart disease, cerebrovascular disease or peripheral vascular disease, renal impairment (serum creatinine >0.15 mmol/L), chronic liver disease, untreated hypothyroidism or hyperthyroidism, concurrent major systemic illness, including malignancy, active major gastrointestinal disease, metabolic bone diseases, or serum ALP >normal, primary hyperparathyroidism, calcium supplements: those consistently using 500 mg/day or more need to be off calcium supplements for 6 months before entering the study; doses <100 mg/day can be continued during the study; doses between 100 and 499 mg/day require intermediate times of withdrawal prior to study entry, current or expected use of oral glucocorticoid drugs during the trial period, current or past use of bisphosphonate therapy in the preceding 2 years, use of hormone replacement therapy within the last 12 months, use of other medication known to cause osteoporosis or interfere with bone metabolism, calciferol supplements > 2000 IU/day (lower doses can be continued during the study).

发起方

niversity of Auckland